Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06974734 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
A Phase 1 study of Carcinoma, Non-Small Cell Lung and Malignant Melanoma, sponsored by Pfizer.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 15
- Study locations
NCT06974734: Active Phase 1 study of Carcinoma, Non-Small Cell Lung and Malignant Melanoma, sponsored by Pfizer.
NCT06974734 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Malignant Melanoma that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 9 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (97% lower). The trial reports 15 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06974734, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Malignant Melanoma, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies. This study is seeking participants who: * have advanced or metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, or pancreatic ductal adenocarcinoma (PDAC); * are able to provide tumor tissue samples; * have measurable disease. All participants will receive while at the clinic PF-08046037 alone as an intravenous (IV) infusion (given directly into a vein) or with sasanlimab as a subcutaneous (SQ) injection (given under the skin) once every 3 weeks. Participants will continue to take the study drug(s) until their cancer is no longer responding or if the patient cannot safely take them. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Primary Outcome
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention
Conditions Studied
Interventions
- DRUG PF-08046037
- DRUG sasanlimab
Study Locations (15)
Connecticut
- Smilow Cancer Hospital - Yale New Haven Health - New Haven
- Yale - New Haven Hospital - Yale Cancer Center - New Haven
- Smilow Cancer Hospital Phase 1 Unit - New Haven
- Smilow Cancer Hospital - Trumbull - Trumbull
Indiana
- Community Health Network, Inc - Indianapolis
- Community Health Network, Inc. - Indianapolis
- Community Health Network, Inc. - Indianapolis
- Community Health Network, Inc. - Indianapolis
Tennessee
- Sarah Cannon Research Institute - Pharmacy - Nashville
- SCRI Oncology Partners - Nashville
- Tristar Centennial Medical Center - Nashville
Colorado
- Presbyterian/ St. Lukes Medical Center - Denver
- Sarah Cannon Research Institute at HealthONE - Denver
Michigan
- START Midwest - Grand Rapids
Other
- Pan American Center for Oncology Trials, LLC - Rio Piedras
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 1 |
What the registry record for NCT06974734 still lists
NCT06974734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which PF-08046037 is the first listed.
NCT06974734 lists 15 locations in 6 states (Connecticut, Indiana, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06974734 about?
NCT06974734 is a clinical study titled "A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies". The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies. This study is seeking participants who: * have advanced or metastatic non-small cell lung cancer (NSCLC), head and neck s...
What is the current status of trial NCT06974734?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2025-05-06. Estimated completion is 2026-04-30.
What conditions does trial NCT06974734 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Malignant Melanoma, Carcinoma, Pancreatic Ductal, Squamous Cell Carcinoma of the Head and Neck (SCCHN).
What interventions are being tested in trial NCT06974734?
The interventions under investigation include: PF-08046037 (DRUG), sasanlimab (DRUG).
Who is sponsoring clinical trial NCT06974734?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06974734 being conducted?
This trial has 15 study locations across Colorado, Connecticut, Indiana, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06974734's enrollment target sits among peer trials
9 128th of 130 higher than 3 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI